 Home > Medical News > Medicines Company News > Zhenbaodao intends to enter the field of biopharmaceuticals with a 16.67% stake in Terris for 400 million

Zhenbaodao intends to enter the field of biopharmaceuticals with a 16.67% stake in Terris for 400 million

 Last Update: 2021-07-06
 Source: Internet
 Author: User

Tags

11 16 plywood

3m company products

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

On the evening of June 15th, Zhenbaodao issued an announcement stating that it had signed an investment cooperation agreement with Zhejiang Teruisi Pharmaceutical Co.
, Ltd.
(hereinafter referred to as Teruisi)
.

This has become the second deployment of Treasure Island in the field of biological medicine after its subsequent efforts to innovate and develop traditional Chinese medicines and chemical medicines in recent years

According to the agreement, Zhenbaodao and Hulin Longpeng Investment Center (Limited Partnership) (hereinafter referred to as Hulin Longpeng), a shareholder holding more than 5% of the shares, will jointly invest in Terris
.

Among them, Treasure Island invested 400 million yuan, accounting for 16.

Teruisi was established in September 2015 with a registered capital of 75.
65 million yuan.
It integrates R&D and commercial production.
It is committed to the development and production of cancer treatment monoclonal antibodies.
It has 11 innovative drugs and biosimilar products under development.
3 products have been approved for clinical trials (Phase I/III), and the technical fields involve targeted therapy, monoclonal antibody coupling (ADC), cancer immunotherapy and other popular fields.
Terris is also China's first successful application of biosimilar drugs in the United States Pharmaceutical company
.

In addition to the Chinese market, Terris also faces the global market, including mainstream pharmaceutical markets in Europe and the United States

Treasure Island said that the investment in Terras is an important measure for strategic transformation and international integration

Source: Corporate Announcement

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

Related Products

L-Ascorbate-2-Monophosphate Feed Grade

CAS No.: 109620-90-8

Feed Grade

Potassium Sorbate from reliable manufacturer

CAS No.: 590-00-1

Food Grade

Doxycycline Hydrochloride

CAS No.: 10592-13-9

Pharmaceutical Grade

Hot Tags

united states jobs(223)

jobs united states(236)

1 year treasury(277)

1 year subscription(296)

single use technology(195)

announcements today(81)

ups united states(221)

united states logo(227)

80 20 company(94)

healthy food name(42)

Hot Articles

The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.